# UTAA17 Injection in the Treatment of Relapsed/Refractory Multiple Myeloma

> **NCT06279026** · NA · RECRUITING · sponsor: **PersonGen BioTherapeutics (Suzhou) Co., Ltd.** · enrollment: 15 (estimated)

## Conditions studied

- Relapsed/Refractory Multiple Myeloma

## Interventions

- **BIOLOGICAL:** UTAA17 Injection

## Key facts

- **NCT ID:** NCT06279026
- **Lead sponsor:** PersonGen BioTherapeutics (Suzhou) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-01
- **Primary completion:** 2027-04-01
- **Final completion:** 2027-07-01
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2024-02-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06279026

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06279026, "UTAA17 Injection in the Treatment of Relapsed/Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06279026. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*